Trial Profile

A Phase 1b/2a Three-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 09 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LY 2880070 (Primary) ; Gemcitabine
Indications Advanced breast cancer; Carcinoma; Colorectal cancer; Endometrial cancer; Gastrointestinal stromal tumours; Ovarian cancer; Pancreatic cancer; Soft tissue sarcoma; Solid tumours; Triple negative breast cancer
Focus Adverse reactions; Proof of concept
Sponsors Esperas Pharma

02 May 2025 Status changed from recruiting to completed.
11 Jan 2023 Planned End Date changed from 1 Jun 2021 to 30 Sep 2025.
11 Jan 2023 Planned primary completion date changed from 1 Mar 2020 to 30 Sep 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com